GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Annexin Pharmaceuticals AB (publ) ANNX.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

9.44

+6.07%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Annexin Pharmaceuticals AB (publ)

Its shares trade on Nasdaq Stockholm under the ticker ANNX.ST. It has been listed since 19 April 2017.

Annexin Pharmaceuticals AB operates as a biotechnology company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-04-19. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The firm maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
19 Apr 2017
Employees
4

Leadership

Pay as last reported

  • Anna Frostegård, MD, PhDChief Scientific & Medical Officer, since 2014
  • Lena Margareta Torlegård, MBADirector, since 2018
  • Erik Johan Frostegård, MD, PhDDirector, since 2016
  • Nils Anders Haegerstrand, PhD, MDChief Executive Officer, since 2018
  • Susan SuchdevChief Operating Officer
  • Carl Henrik PalmChief Financial Officer, since 2019
  • Uli Alf Hacksell, PhDChairman, since 2021
  • MÃ¥rten Österlund, PhDDirector, since 2021
  • Carl-Fredrik LindnerDirector, since 2017
  • Gisela Marie Sitbon, PhDDirector, since 2017

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Operates as a biotechnology company with a focus on pharmaceuticals.
  • Owns a comprehensive patent portfolio for treating diseases related to blood vessel damage and inflammation.
  • Maintains a patented cell line for manufacturing Annexin A5.

Weaknesses

  • Employs only 4 full-time employees.
  • IPO occurred in 2017, indicating limited operational history.
  • Main product ANXV is for emergency treatment of cardiovascular disease with blood vessel damage.

Opportunities

  • ANXV has potential for emergency treatment of cardiovascular disease with blood vessel damage and inflammation.
  • Patented production process could support future expansion.
  • Comprehensive patent portfolio may attract partnerships or licensing deals.

Threats

  • Limited employee count may hinder growth and operational capacity.
  • Dependence on a single product (ANXV) for revenue.
  • Biotechnology sector faces high regulatory and development risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.